GLP1R and prediabetes syndrome: After standardizing with respect to the relevant confounders and estimating the average treatment effects among the treated, GLP‐1 RA initiation in patients with prediabetes was associated with a 1‐year risk of 55.68% (95% CI: 52.84–58.51) of nonadherence, whereas the risk associated with metformin initiation was 34.79% (95% CI: 32.09–37.50), yielding a RR of 1.60 (95% CI: 1.45;1.75, p < 0.001) for GLP‐1 RA initiation compared to metformin initiation.